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Background:  Several studies in Western populations have indicated that metabolic syndrome (MetS) is inferior to the Framing-
ham risk score (FRS) in predicting coronary heart disease (CHD). However there has been no study about the predictability of 
MetS vs. FRS for CHD in Korea. 
Methods:  Among the 43,145 persons from the third Korea National Health and Nutrition Examination Survey in 2005, labora-
tory test and nutritional survey data from 5,271 persons were examined. Participants were also asked to recall a physician’s diag-
nosis of CHD.
Results:  The median age was 46 (range, 20 to 78) in men (n=2,257) and 44 (range, 20 to 78) years in women (n=3,014). Preva-
lence of self-reported CHD was 1.7% in men and 2.1% in women. Receiver operating characteristic curves and their respective 
area under the curve (AUC) were used to compare the ability of the FRS and the number of components of MetS to predict self-
reported CHD in each sex. In men, AUC of FRS was significantly larger than that of MetS (0.767 [0.708 to 0.819] vs. 0.677 [0.541 
to 0.713], P<0.01). In women, AUC of FRS was comparable to that of MetS (0.777 [0.728 to 0.826] vs. 0.733 [0.673 to 0.795]), 
and was not significant. 
Conclusion:  The data suggested that FRS was more closely associated with CHD compared to MetS in Korean men. 
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INTRODUCTION
Metabolic syndrome (MetS), defined as a cluster of cardiovas-
cular risk factors, has been considered to be a useful concept 
for prevention of the rapidly growing incidence of coronary 
heart disease (CHD) [1-3]. The concept of MetS has also been 
widely used for the co-management of multiple cardiovascular 
risk factors including diabetes, hypertension, and dyslipidemia 
in high risk persons for optimal outcomes [1,4]. Furthermore, 
it has been widely promoted as a means of identifying patients 
for life style modification to reduce risk factors and disease in-
cidence, in particular CHD [5-8].
  Many studies have shown that whether defined on the basis 
of National Cholesterol Education Program (NCEP) criteria 
[9-21] or World Health Organization (WHO) criteria [2,10,11, 
18,22], MetS is associated with significantly increased risk of 
developing CHD. Several recent studies conducted in Western 
populations have indicated that MetS is inferior to the Fram-
ingham risk score (FRS), a traditional risk scoring system, in 
predicting CHD [5,19,21,23]. However, there has been no study 
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examining the predictability of MetS vs. FRS with regard to 
CHD in Korea. 
  The Korean Ministry of Health and Welfare has conducted 
the Korean National Health and Nutrition Examination Survey 
(KNHANES) since 1998. We assessed the relative associations 
of MetS using NCEP criteria [24] vs. FRS with self-reported 
CHD in a national representative cohort of Republic of Korea. 
METHODS
Study population
This study was based on data obtained from the third 
KNHANES (KNHANES III) among non-institutionalized ci-
vilians in the Republic of Korea, conducted by the Korean 
Ministry of Health and Welfare in 2005. This survey was a na-
tionwide representative study using a stratified, multistage 
probability sampling design for the selection of household 
units. The survey consisted of a health interview, health behav-
ior, health examination, and nutrition components. A total of 
34,145 individuals from these sampling frames were included 
in the health interview survey. The FRS can be applied to per-
sons aged 20 to 79 years, so we excluded persons under 20 years 
and over 79 years. Among this group, 5,271 persons aged 20 to 
79 years were identified as participants, using laboratory tests 
and nutritional survey data. 
Health examination survey and laboratory test 
Trained interviewers visited each participant’s dwelling and 
administered a standardized questionnaire on smoking and 
regular exercise. A dietary recall method was used to collect 
data on food items consumed by participants during the past 
24 hours. The participants were also asked to recall a physician’s 
diagnosis of CHD (angina or myocardial infarction). Height 
and weight were obtained using standardized techniques and 
equipment. Height was measured to the nearest 0.1 cm using a 
portable standiometer (Seriter, Bismarck, ND, USA). Weight 
was measured to the nearest 0.1 kg using a calibrated balance 
beam scale (Giant-150N; Hana, Seoul, Korea). Body mass in-
dex (BMI) was calculated by dividing weight by height squared 
(kg/m
2). Waist circumference (WC) was measured on stand-
ing participants with a soft tape midway between the lowest 
rib and the iliac crest. Systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were measured by standard meth-
ods using a sphygmomanometer with the patient in a sitting 
position. Three measurements were made on all subjects at 
5-minute intervals; the average of the second and third mea-
surements was used in the analysis. Blood samples were col-
lected in the morning after fasting for at least 8 hours. Fasting 
plasma glucose (FPG), total cholesterol (TC), triglyceride (TG), 
and high density lipoprotein cholesterol (HDL-C) levels were 
measured in a central and certified laboratory; an Advia 1650 
(Siemens, Tarrytown, NY, USA) was used. Low density lipo-
protein cholesterol (LDL-C) was estimated indirectly using 
the Friedwald formula: LDL-C=TC–{HDL-C+(TG/5)}, for 
subjects with TG levels <400 mg/dL.
Definitions of MetS and FRS
MetS as defined by NCEP criteria comprises three or more of 
the following [24]: 1) FPG level of at least 100 mg/dL or current 
anti-diabetes medication; 2) serum TG level of at least 150 mg/
dL; 3) serum HDL-C level lower than 40 mg/dL for men and 
50 mg/dL for women; 4) SBP of at least 130 mm Hg or DBP of 
at least 85 mm Hg or current anti-hypertensive medication; 
and 5) WC of at least 90 cm for men and 80 cm for women [25]. 
The FRS for CHD was calculated for each participant [26,27], 
and participants were categorized according to quintiles of 
risk score in each sex.
Statistical analyses
Data are presented as mean±standard deviation or percent. 
Statistical analysis was performed using SPSS for Windows 
version 18.0 (SPSS Inc., Chicago, IL, USA). Independent t-test 
and χ2 test was done for comparison of clinical and biochemi-
cal characteristics between each sex (Table 1). Independent t-
test and χ2 test was done for comparison of clinical character-
istics according to self-reported CHD in each sex (Table 2). 
Receiver operating characteristic (ROC) curves and their re-
spective area under the curve (AUC) were used to compare 
the ability of the FRS and the number of metabolic abnormali-
ties to predict self-reported CHD in each sex (Fig. 1) [28]. Lo-
gistic regression analysis for self-reported CHD was done to 
compare R
2 between model 1 with variables of five compo-
nents of MetS and model 2 with variables of age, current smok-
ing, and those variables in model 1 (Table 3). All probability 
values were two-tailed, and statistical significance was defined 
as P<0.05.
Ethics statement
This study was approved by the Institutional Review Board of 
the Ilsan Paik Hospital (IB-2-1105-013).239
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RESULTS
Table 1 summarizes the comparison of clinical characteristics 
in both genders of the study population. There was no differ-
ence in age between men (mean, 46 years; range, 20 to 78 years) 
and women (mean, 44 years; range, 20 to 78 years). Frequency 
of current smoking in men was markedly higher compared to 
women (45.9% vs. 4.3%, P<0.001). Men were more obese 
compared to women in comparison of BMI and WC. SBP and 
DBP in men were higher than in women. However, there was 
no difference in chance of current anti-hypertensive medica-
tions between men and women. Serum TG in men was higher 
and serum HDL-C in men was lower than in women. Howev-
er, there was no difference in chance of current anti-lipid med-
ications between men and women. FPG and chance of currently 
taking anti-diabetes drugs in men was higher than in women. 
Prevalence of MetS defined by NCEP-Adult Treatment Panel 
III (ATP III) criteria in men was higher than that in women 
(30.9% in men vs. 27.8% in women, P=0.016). Contrary to 
comparison of MetS, there was no difference in CHD preva-
lence between genders. Prevalence of self-reported CHD was 
1.7% in men and 2.1% in women. 
Table 1. Clinical characteristics of the study population 
Characteristic
Men 
(n=2,257)
Women 
(n=3,014)
P value
Age, mean (range), yr 46 (20-78) 44 (20-78) NS
Current smoking, % 45.9 4.3 <0.001
Exercise 3x/wk, % 33.6 34.4 NS
Daily calories intake, kcal 2,351±916 1,807±686 <0.001
Daily fat intake, g 49.0±36.7 36.7±28.3 <0.001
Daily alcohol intake, g 17.8±45.0 2.6±11.3 <0.001
BMI, kg/m
2 24.0±3.1 23.5±3.4 <0.001
Waist circumference, cm 84.3±8.7 78.4±9.5 <0.001
SBP, mm Hg 122.7±16.0 116.0±18.1 <0.001
DBP, mm Hg 80.7±10.3 74.7±10.3 <0.001
Anti-hypertensive  
medication, %
11.3 12.6 NS
Total cholesterol, mg/dL 185.2±34.6 184.5±35.5 NS
LDL-C, mg/dL 113.3±30.2 115.0±30.3 NS
Triglyceride, mg/dL 163.4±157.8 115.0±80.5 <0.001
HDL-C, mg/dL 42.4±10.2 47.2±10.9 <0.001
Anti-lipid medication, % 1.4 1.4 NS
FPG, mg/dL 98.1±26.1 92.9±19.5 <0.001
Anti-diabetes medication, % 7.3 5.1 <0.001
Hormone replacement  
therapy, %
7.0
MetS, % 30.9 27.8 0.016
Self-reported CHD, % 1.7 2.1 NS
Values are presented as mean±standard deviation or percent. 
NS, not significant; BMI, body mass index; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure; LDL-C, low density lipoprotein 
cholesterol; HDL-C, high density lipoprotein cholesterol; FPG, fast-
ing plasma glucose; MetS, metabolic syndrome; CHD, self-reported 
coronary heart disease.
Fig. 1. Receiver operating characteristic curves for prediction 
of self-reported coronary heart disease by numbers of metabol-
ic syndrome (MetS) components and quintiles of Framingham 
risk score (FRS) in each sex. (A) In men, area under the curve 
(AUC) of FRS vs. MetS; 0.767 (0.708 to 0.819) vs. 0.677 (0.541 
to 0.713), P<0.01. (B) In women, AUC of FRS vs. MetS; 0.777 
(0.728 to 0.826) vs. 0.733 (0.673 to 0.795), not significant. 
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  Table 2 summarizes the data concerning clinical character-
istics according to self- reported coronary heart disease in each 
sex. In men, participants with CHD were older, and showed 
higher SBP and FPG, and greater probability of current anti-
hypertensive medications, anti-lipid medications, and anti-di-
abetes medications than participants without CHD. In wom-
en, participants with CHD were older, and showed higher BP, 
cholesterol, TG, FPG, and greater probability of current anti-
hypertensive medications, anti-lipid medications, and anti-di-
abetes medications than participants without CHD. There was 
no difference in chance of hormone replacement therapy be-
tween women with CHD and women without CHD (6.9% vs. 
8.1%). In participants with self-reported CHD, prevalence of 
MetS was 50.0% in men and 61.3% in women. FRS was 13.31± 
2.59 in men and 12.02±4.75 in women.
  ROC curves and their respective AUC were used to compare 
the ability of the FRS and the number of components of MetS 
predicting CHD in both genders (Fig. 1). In men, AUC of FRS 
(mean, 0.767; range, 0.708 to 0.819) was significantly larger 
than that of MetS (mean, 0.677; range, 0.541 to 0.713) (P<0.01). 
In women, AUC of FRS was comparable to that of MetS (mean, 
0.777; range, 0.728 to 0.826 vs. mean, 0.733; range, 0.673 to 
0.795) (not significant). When using a different criterion of 
FPG of 110 mg/dL or WC for MetS, similar results of ROC 
analyses were observed (data not shown). 
  In men, in the logistic regression analysis model with vari-
ables of five components of MetS (model 1), hypertension and 
abnormal glucose were significant determinants for CHD. 
However, after adjusting for age, current smoking (model 2), 
hypertension and abnormal glucose were not significant de-
Table 2. Clinical characteristics according to self-reported coronary heart disease in each sex
Characteristic
Men (n=2,257) Women (n=3,014)
CHD (-) (n=2,219) CHD (+) (n=38) P value CHD (-) (n=2,952) CHD (+) (n=62) P value
Age, yr 46.5±14.0 62.1±8.3 <0.001 45.9±14.7 60.6±11.0 <0.001
Current smoking, % 46.1 34.2 NS 4.3 4.8 NS
Exercise 3x/wk, % 33.3 50.0 0.037 34.3 37.1 NS
Daily calories intake, kcal 2,357±919 2,057±697 0.016 1,813±689 1,541±469 0.003
Daily fat intake, g 49.2±36.7 33.9±37.9 0.021 37.1±28.5 21.7±13.8 <0.001
Daily alcohol intake, g 18.0±45.2 8.9±29.4 NS 2.6±11.4 1.7±6.2 NS
BMI, kg/m
2 24.0±3.1 24.5±3.2 NS 23.5±3.4 24.3±3.1 0.044
Waist circumference, cm 84.3±8.7 87.3± 9.7 NS 78.3±9.5 83.6±9.5 <0.001
SBP, mm Hg 122.5±15.8 134.4±22.6 <0.001 115.6±18.0 130.7±19.5 <0.001
DBP, mm Hg 80.8±10.3 81.7±10.1 NS 74.6±10.2 80.9±10.4 <0.001
Anti-hypertensive medication, % 10.8 36.8 <0.001 11.7 54.8 <0.001
Total cholesterol, mg/dL 185.3±34.7 182.1±29.7 NS 184.3±35.0 200.1±53.2 0.001
LDL-C, mg/dL 113.4±30.2 111.5±29.9 NS 114.7±29.9 126.8±44.0 0.042
Triglyceride, mg/dL 163.8±158.9 150.3±67.8 NS 114.0±78.0 164.2±140.7 <0.001
HDL-C, mg/dL 42.4±10.2 40.5±10.7 NS 47.3±10.9 42.1 ± 10.6 <0.001
Anti-lipid medication, % 1.2 10.5 0.002 1.3 8.1 0.002
FPG, mg/dL 98.0±26.1 106.1±24.4 NS 92.7±19.3 102.5±26.4 <0.001
Anti-diabetes medication, % 7.0 26.3 <0.001 4.8 21.0 <0.001
Hormone replacement therapy, % 6.9 8.1 NS
FRS 8.11±6.23 13.31±2.59 <0.001 4.68±7.64 12.02±4.75 <0.001
MetS, % 30.6 50.0 0.013 27.1 61.3 <0.001
Values are presented as mean±standard deviation or percent. 
CHD, self-reported coronary heart disease; NS, not significant; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pres-
sure; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; FPG, fasting plasma glucose; FRS, Framingham 
risk score; MetS, metabolic syndrome.241
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terminants for CHD. In model 2 with variables of age, current 
smoking, and five components of MetS, age was the only sig-
nificant determinant for CHD in men. The R
2 in model 1 was 
very low, but by including age and current smoking as addi-
tional variables, the R
2 in model 2 was increased from 0.048 to 
0.148 in men (Table 3). In women, hypertension was the only 
significant determinant for CHD in model 1 and even after 
adjusting for age and current smoking, the significance per-
sisted in model 2. In model 2, age and hypertension were sig-
nificant determinants for CHD in women. Contrary to the 
finding that the R
2 increased when age and current smoking 
were included as additional variables in men, in women, the 
R
2 in model 2 was comparable to that in model 1 (model 1, 
R
2=0.124; model 2, R
2=0.147) (Table 3).
DISCUSSION
In this nation-wide representative cohort of Koreans, MetS was 
comparable to the predictability of FRS in the ROC analysis for 
CHD in Korean women. However, the data showed that the 
FRS was more closely associated with CHD compared to MetS 
in Korean men, which suggests the limitation of MetS for the 
prediction of CHD in Koreans. 
  There have been a few reports comparing MetS and FRS for 
the prediction of CHD. FRS was a better predictor of CHD 
than MetS in a 20-year prospective study of 5,128 men in the 
United Kingdom aged 40 to 59 years with no history of CHD 
[23]. Results from a 13.7-year follow-up cohort study includ-
ing 1,471 men and women in Scotland suggested that MetS is 
not a useful tool for predicting the risk of CHD [29]. In that 
study, the authors reported that the AUC for MetS was lower 
than that of FRS (0.576 vs. 0.752, P<0.001). Both results were 
comparable to our findings, suggesting that these findings are 
applicable across nations. 
  MetS has been widely used for predicting CHD in clinical 
practice. Disappointingly, MetS was not superior to FRS for 
prediction of CHD in our Korean population. Especially in 
men, MetS was inferior to FRS. Considering that FRS is quite 
easily calculated compared to MetS, MetS has doubtful clinical 
usefulness for CHD. These results could be easily anticipated 
considering each criterion of MetS and FRS. In present study, 
the R
2 of the logistic regression analysis model for CHD with 
variables of five components of MetS was only 0.048 in men. 
However, after including age and current smoking as addition-
al variables, the R
2 increased from 0.048 to 0.148. Age was the 
only differentia for CHD in the regression model with age, cur-
rent smoking, hypertension, high TG, low HDL-C, and abdom-
inal obesity as variables in men. Contrary to the results in men, 
the R
2 in model 2 was comparable to that in model 1 (model 1, 
R
2=0.124; model 2, R
2=0.147) in women. This finding was 
compatible with our results of the ROC analyses. The relatively 
lower predictability of CHD for MetS compared to FRS could 
Table 3. Logistic regression analyses for self-reported coronary heart disease in each sex
Variable
Men Women
Model 1 (each variable  
of MetS)
Model 2 (age, current smok-
ing, and variables of model 1)
Model 1 (each variable  
of MetS)
Model 2 (age, current smok-
ing, and variables of model 1)
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Hypertension 2.23 (1.08-4.63) 0.031 1.31 (0.63-2.73) 0.405 6.42 (3.40-12.14) <0.001 3.56 (1.78-7.12) <0.001
High triglyceride 0.83 (0.42-1.66) 0.596 1.19 (0.59-2.42) 0.631 0.99 (0.56-1.75) 0.962 0.94 (0.53-1.65) 0.817
Low HDL-C 1.17 (0.60-2.30) 0.647 1.13 (0.58-2.23) 0.719 1.80 (0.93-3.47) 0.083 1.71 (0.88-3.31) 0.115
Abnormal glucose 2.59 (1.31-5.10) 0.006 1.70 (0.86-3.37) 0.127 1.57 (0.91-2.74) 0.108 1.37 (0.79-2.39) 0.261
Abdominal obesity 1.08 (0.53-2.20) 0.844 1.02 (0.50-2.09) 0.953 1.22 (0.68-2.19) 0.506 1.10 (0.62-1.96) 0.744
Age 1.09 (1.06-1.13) <0.001 1.04 (1.02-1.07) <0.001
Current smoking 0.88 (0.44-1.77) 0.716 0.88 (0.27-2.91) 0.833
R
2 0.048 0.148 0.124 0.147
Definition of each component of metabolic syndrome: hypertension, systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm 
Hg or current anti-hypertensive medication; high triglyceride, serum triglyceride ≥150 mg/dL; low HDL-C, serum HDL-C <40 mg/dL for 
men and <50 mg/dL for women; abnormal glucose, fasting plasma glucose ≥100 mg/dL or current anti-diabetes medication; abdominal obe-
sity, waist circumference ≥90 cm for men and 80 cm for women.
MetS, metabolic syndrome; OR, odds ratio; CI, confidence interval; HDL-C, high density lipoprotein cholesterol.242
Kang HM, et al.
Diabetes Metab J 2012;36:237-244 http://e-dmj.org
be explained by the fact that age was not included in the NCEP-
ATP III criteria for MetS. It has been presumed that MetS is a 
positive stimulus of CHD prevention and effective manage-
ment. However, the present results suggest that the main role 
of the concept of MetS may be greater public awareness and 
education of the necessity of co-management of CHD risk fac-
tors. Traditional risk factors, including age, smoking, and cho-
lesterol, which are not included in the criteria for MetS, should 
be continuously stressed for CHD.
  We did not consider current anti-lipid medications for de-
tection of high TG or low HDL-C to define MetS. Because ex-
act history for anti-lipid medication was not available in the 
KNHANES 2005, we could not distinguish anti-cholesterol 
medication from anti-triglyceride medication from the datas-
et. This may affect the study results. However, considering that 
the number of participants taking anti-lipid medications was 
relatively small (1.4%) and that anti-lipid medication could af-
fect the prevalence of both FRS and MetS, we did not think 
this affected the major finding of this study. As other studies 
have reported that hormone replacement therapy is associated 
with CHD [30,31], we should consider the presence of hor-
mone replacement therapy in the study of CHD. In our study, 
there was no difference in hormone replacement therapy be-
tween participants with CHD and those without CHD (8.1% 
vs. 6.9%).
  In-depth analyses of the KNHANES 2005 by the Centers 
for Disease Control and Prevention (KCDC) and the Korea 
Institute or Health and Social Affairs (KIHASA) [32] reported 
that age-adjusted self-reported CHD prevalence in men was 
16.6/1,000 persons and 21.6/1,000 persons for women. In our 
analyses there was no difference in chances of taking anti-hy-
pertensive medication or anti-lipid medication between men 
and women. However, SBP, DBP, serum TG, and FPG in men 
were higher than in women. A larger proportion of men took 
anti-diabetes medication compared to women. Moreover, 
about 46% of men were current smokers. In spite of the higher 
accompanying rate of CHD risk factors in men compared to 
women, there was no difference in self-reported CHD between 
genders. The reason for this finding is not clear. Further study 
is needed to elucidate the reason. There are also some limita-
tions to this study. First, this was not a longitudinal follow-up 
study, but a cross-sectional observational study. In this study, 
we evaluated clinical and biochemical parameters of partici-
pants with past history of CHD in 2005 KNHANES. The rela-
tively low R
2 in logistic regression analyses for CHD using well-
established risk factors as variables suggests that this study has 
limitations. The second limitation could be recall bias. The 
presence of CHD was based on a questionnaire concerning a 
previous diagnosis of CHD, which was not confirmed by med-
ical records. Neither an electrocardiogram nor a questionnaire 
concerning heart symptoms (e.g., Rose questionnaire) was 
available. If there was a difference in the degree of recall bias 
between genders, this difference could affect the prevalence of 
self-reported CHD. The strength of this study is that it was 
conducted based on nationally representative data of the civil-
ian, non-institutionalized Korean population. However, with 
these limitations, we could not confirm the results of this study 
and another well-designed follow-up study will be needed.
  In conclusion, we observed the inferiority of MetS compared 
to FRS for prediction of self-reported CHD using ROC analy-
sis in Korean men. The usefulness of MetS for the prediction 
of CHD in the Korean population should be confirmed in an-
other longitudinal follow-up study. 
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